Prognosis is the term describing the odds of successful treatment, recovery and survival of an individual affected by a disease. Basal cell carcinoma, squamous cell carcinoma and melanoma prognosis (as well as prognosis for more rare types of skin cancer) depend on a combination of factors.
Though outcomes vary on a case-by-case basis, skin cancer prognosis follows a general pattern by type:
Staging is an important part of determining skin cancer prognosis. Skin cancer is usually staged using the American Joint Commission on Cancer (AJCC) TNM staging system. This system accounts for three aspects of the cancer lesion:
For the three most common types of skin cancer (basal cell carcinoma, squamous cell carcinoma and melanoma), lesions that are identified and receive skin cancer treatment in their earliest stages tend to have better prognosis. For example, according to the American Cancer Society (2010), the five-year survival rate for melanoma found in its earliest stage (IA) is 97 percent, while for late-stage (stage IV) melanoma the five-year survival rate is approximately only 40 percent.
Though type and stage are the most significant components determining prognosis, other factors contribute as well:
American Cancer Society. (2010). Melanoma skin cancer. Retrieved July 14, 2010, from http://www.cancer.org/acs/groups/cid/documents/webcontent/003120-pdf.pdf
University of Maryland Medical Center. (2009). Skin cancer. Retrieved July 14, 2010, from http://www.umm.edu/altmed/articles/skin-cancer-000029.htm
American Cancer Society. (2010). What are the survival rates for melanoma by stage? Retrieved July 14, 2010, from http://www.cancer.org/Cancer/SkinCancer-Melanoma/DetailedGuide/melanoma-skin-cancer-survival-rates